haematology
R-IPI — Revised International Prognostic Index for DLBCL
Risk stratification for DLBCL treated with R-CHOP (Sehn 2007). Sums 5 adverse factors. Original IPI thresholds re-grouped into 3 outcomes.
Score interpretation
Very good (4-y PFS ~94%) 0
→ Standard R-CHOP × 6 cycles with interim PET. Excellent prognosis.
Good (4-y PFS ~80%) 1–2
→ Standard R-CHOP × 6 cycles. Consider clinical trial enrolment if available.
Poor (4-y PFS ~55%) 3–5
→ Consider intensified regimen (Pola-R-CHP per POLARIX) or trial enrolment. CNS prophylaxis if high CNS-IPI; routine PET assessment; maintain dose intensity.
Interpretation bands for the R-IPI. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- International Prognostic Index (IPI) for DLBCL · Lymphoma
- Ann Arbor Staging for Lymphoma · Lymphoma
- CNS International Prognostic Index (CNS-IPI) for DLBCL · Lymphoma
- NCCN-IPI for Diffuse Large B-Cell Lymphoma · Lymphoma
- MALT Lymphoma International Prognostic Index (MALT-IPI) · Lymphoma
- Mantle Cell Lymphoma International Prognostic Index (MIPI) · Lymphoma
Drugs
Pathways
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158
- Sickle Cell Crisis · BSH 2021 / BCSH
- Neutropenic Sepsis · NICE CG151 2012 / ESMO
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.